Literature DB >> 21565270

Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.

V V S Rajendra Prasad1, G J Peters, Clara Lemos, Ietje Kathmann, Y C Mayur.   

Abstract

A series of novel N(10)-substituted acridone derivatives bearing alkyl side-chain with tertiary amine groups at the terminal position were evaluated for their in vitro cytotoxic effects against drug sensitive and resistant cancer cell lines. All the molecules were designed on the basis of hydrogen bond acceptors, carbonyl, fluoro groups with precise spatial separation and structural features of lipophilicity, positive charge at neutral pH and presence of aromatic rings. The in vitro cytotoxic effects in comparison with reference drugs doxorubicin (DX) and C(1311) against cancer cell lines SW 1573, SW 1573 2R 160 (Pg-P expressing) which are non-small cell lung cancer cells, human embryo kidney cells HEK 293, HEK 293 MRP4, HEK 293 MRP5i, human promyelocytic leukemia sensitive cell line HL-60, including its multidrug cross-resistant of two main (P-gp and MRP) phenotype sublines vincristine resistant HL-60/VINC and doxorubicin resistant HL-60/DX cancer cell lines are presented. Compounds 14, 15 and 16 exhibited highest cytotoxicity among the derivatives. On the other hand, the in vitro cytotoxic activity of compound 14 (with butyl side-chain and tertiary amino group β-hydroxy ethyl piperizine) against resistant cancer cell lines indicate that it might be a promising new hit for further development as an anti-MDR agent. The non-covalent interaction of these molecules with DNA duplexes have been investigated by ESI-MS technique. The results indicate, these acridone derivatives interact with duplex DNA by intercalation, possesses higher affinity to GC than AT base pairs of the DNA and they could not interact non-covalently with the minor grooves of the DNA. The ability of acridones to inhibit calmodulin dependent cAMP phosphodiesterase has been determined. The results suggest that acridones inhibit the Ca(2+)/calmodulin stimulated cAMP-phosphodiesterase activity and have no direct effects on the enzyme itself and a strong correlation between calmodulin inhibition and cytotoxicity against HL-60/VINC and HL-60/DX MDR cancer cell lines.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565270     DOI: 10.1016/j.ejps.2011.04.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Acridone suppresses the proliferation of human breast cancer cells in vitro via ATP-binding cassette subfamily G member 2.

Authors:  Licheng Xu; Shuyan Li; Zhi Liang; Haixia Lin; Rongzhan Fu
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

Review 2.  Medicinal chemistry of acridine and its analogues.

Authors:  Parteek Prasher; Mousmee Sharma
Journal:  Medchemcomm       Date:  2018-08-14       Impact factor: 3.597

3.  Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma.

Authors:  Malobika Chakravarty; Piyali Ganguli; Manikanta Murahari; Ram Rup Sarkar; Godefridus Johannes Peters; Y C Mayur
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

4.  Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia.

Authors:  Magnus Borssén; Lars Palmqvist; Kristina Karrman; Jonas Abrahamsson; Mikael Behrendtz; Jesper Heldrup; Erik Forestier; Göran Roos; Sofie Degerman
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

5.  Acridone derivative 8a induces oxidative stress-mediated apoptosis in CCRF-CEM leukemia cells: application of metabolomics in mechanistic studies of antitumor agents.

Authors:  Yini Wang; Dan Gao; Zhe Chen; Shangfu Li; Chunmei Gao; Deliang Cao; Feng Liu; Hongxia Liu; Yuyang Jiang
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.